Good day, everyone, and welcome to Pfizer Pflash, a spotlight on the PD-1 VEGF bispecific PF-4404 clinical development strategy. Today's call is being recorded. At this time, I would like to turn the ...
Platform leverages muscle biology to de-risk development and identify new therapeutic targets ahead of clinical entry ...
Wugen, Inc., a clinical-stage biotechnology company developing allogeneic, off-the-shelf cell therapies for the treatment of ...
SHELTON, CONNECTICUT / ACCESS Newswire / October 15, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), reports that an analyst research report was published on the Company that explains ...
MELBOURNE, Australia and NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, today ...
Designed to encourage interaction and collaboration, SCOPE X emphasizes detailed case studies, peer-driven discussions, and ...
Experienced R&D leader with a track record of advancing innovative therapies from early development to global approval — ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results